AMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $167.23 Million
Wall Street analysts expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will report sales of $167.23 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for AMAG Pharmaceuticals’ earnings, with the highest sales estimate coming in at $172.58 million and the lowest estimate coming in at $161.86 million. AMAG Pharmaceuticals reported sales of $143.78 million in the same quarter last year, which suggests a positive year over year growth rate of 16.3%. The business is scheduled to report its next quarterly earnings results before the market opens on Thursday, November 2nd.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year sales of $167.23 million for the current year, with estimates ranging from $638.99 million to $661.00 million. For the next financial year, analysts expect that the business will post sales of $546.78 million per share, with estimates ranging from $481.01 million to $584.07 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. During the same period last year, the company posted $1.45 EPS. The company’s revenue was up 24.3% on a year-over-year basis.
A number of equities research analysts have recently issued reports on AMAG shares. Cantor Fitzgerald restated a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Cowen and Company restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Finally, Morgan Stanley assumed coverage on shares of AMAG Pharmaceuticals in a research note on Friday, September 8th. They issued an “overweight” rating and a $26.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $26.92.
Several hedge funds and other institutional investors have recently bought and sold shares of AMAG. State of Alaska Department of Revenue boosted its holdings in AMAG Pharmaceuticals by 81.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 3,081 shares during the period. Municipal Employees Retirement System of Michigan boosted its holdings in AMAG Pharmaceuticals by 6.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 510 shares during the period. Mason Street Advisors LLC boosted its holdings in AMAG Pharmaceuticals by 7.4% in the 1st quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after purchasing an additional 554 shares during the period. Sei Investments Co. boosted its holdings in AMAG Pharmaceuticals by 0.7% in the 1st quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after purchasing an additional 54 shares during the period. Finally, Karp Capital Management Corp bought a new stake in AMAG Pharmaceuticals in the 1st quarter valued at $232,000.
AMAG Pharmaceuticals (AMAG) opened at 16.05 on Tuesday. AMAG Pharmaceuticals has a 52 week low of $15.20 and a 52 week high of $36.83. The stock’s 50 day moving average is $18.35 and its 200-day moving average is $18.95. The stock’s market capitalization is $566.37 million.
ILLEGAL ACTIVITY NOTICE: “AMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $167.23 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/amag-pharmaceuticals-inc-amag-expected-to-announce-quarterly-sales-of-167-23-million.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.